Edition:
United Kingdom

Mitsubishi Tanabe Pharma Corp (4508.T)

4508.T on Tokyo Stock Exchange

2,289JPY
6:00am GMT
Change (% chg)

¥10 (+0.44%)
Prev Close
¥2,279
Open
¥2,291
Day's High
¥2,297
Day's Low
¥2,277
Volume
906,400
Avg. Vol
1,208,415
52-wk High
¥2,748
52-wk Low
¥2,197

Select another date:

Wed, Dec 20 2017

BRIEF-Mitsubishi Tanabe Pharma updates license agreement with Kolon Life Secience on Invossa

* Says it notified Kolon Life Secience, Inc. (KLS) that the co seeks to cancel the license agreement between the co and KLS for Invossa, a cell therapy product for improvement of knee osteoarthritis symptoms

BRIEF-Mitsubishi Tanabe Pharma completes purchase of NeuroDerm

Oct 18Mitsubishi Tanabe Pharma Corp * Says it completed purchase of NeuroDerm Ltd * Purchase plan was announced on July 24 Source text in Japanese:https://goo.gl/LcG5Lm Further company coverage: (Beijing Headline News)

BRIEF- Mitsubishi Tanabe Pharma sells drug sales unit

* Says it sold 100 percent stake in a drug sales unit to Nipro, on Oct. 1

BRIEF-Neuroderm calls shareholders meeting to approve Mitsubishi Tanabe acquisition

* Neuroderm announces extraordinary general meeting of shareholders to approve acquisition by Mitsubishi Tanabe Pharma Corporation Source text for Eikon: Further company coverage:

Mitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 billion

TOKYO/TEL AVIV Japan's Mitsubishi Tanabe Pharma Corp has agreed to buy Israeli drug maker Neuroderm for $1.1 billion in cash as part of a strategy to grow its business in the United States.

UPDATE 3-Mitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 bln

* Neuroderm shares up 15 pct in premarket trade (Adds Neuroderm shares up 15 pct in premarket trade)

Japan's Mitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 bln

TOKYO, July 24 Japan's Mitsubishi Tanabe Pharma Corp said on Monday it will acquire Israeli drug maker Neuroderm for $1.1 billion in an all-cash deal to expand its overseas business.

BRIEF- Mitsubishi Chemical Holdings consolidated subsidiary to buy NeuroDerm for about $1.1 bln

* Says its consolidated subsidiary Mitsubishi Tanabe Pharma Corp will buy NeuroDerm Ltd, for about $1.1 billion (about 124.1 billion yen), $39 per share, effective October

BRIEF-Neuroderm enters definitive agreement to be acquired by Mitsubishi Tanabe Pharma for $1.1 bln

* Neuroderm enters definitive agreement to be acquired by Mitsubishi Tanabe Pharma corporation for US$1.1 billion in cash

Select another date: